Naloxone Doesn't Touch It: A Veterinary Sedative Is Quietly Taking Over Where Xylazine Left Off

If you gave someone naloxone this year and they stayed sedated anyway — breathing, but not waking up the way naloxone usually makes people wake up — you may have already met medetomidine without a name for it.

The drug supply just found something naloxone can’t touch, and most of the country’s overdose-response training hasn’t caught up.

Medetomidine is a veterinary sedative, used legitimately to tranquilize large animals, and it is up to 100 to 300 times more potent than xylazine — the “tranq” adulterant that spent the last several years earning its own headlines for the necrotic skin wounds it caused in people who injected it alongside fentanyl. Medetomidine doesn’t produce those wounds. It produces something arguably more dangerous precisely because it looks, at first, like ordinary sedation: profound drowsiness, slowed breathing, a heart rate and blood pressure that crash, and then — when it wears off — a withdrawal syndrome of severe hypertension, racing heart, and delirium that has nothing to do with opioids and everything to do with a different class of drug most emergency responders were never trained to withdrawal-manage. Naloxone, built to reverse opioid receptors, does nothing to any of it. According to a CDC Health Alert Network notice, forensic detections of medetomidine in drug samples rose from 247 in 2023 to 2,616 in 2024 to more than 8,200 in 2025 — a trajectory that outpaces even xylazine’s early spread. Ninety-eight percent of medetomidine-positive samples also contained fentanyl, meaning it is arriving as an uninvited passenger in supply that people already believe they understand.

The geography is uneven — the DEA’s public safety advisory puts more than half of detections in the Northeast and another third in the Midwest — but supply adulterants have a track record of not staying regional for long. Xylazine started in Philadelphia and spread coast to coast within a few years; there’s no chemistry reason medetomidine stays put either.

For harm reduction programs, the actionable change is immediate: test strips built for fentanyl and xylazine don’t detect medetomidine, and standard overdose-response training scripts (“give naloxone, rescue breaths, more naloxone”) don’t include the recognition step for a sedation that naloxone simply won’t lift. If you run a syringe service program or train first responders, this is the week to ask your test-strip supplier whether a medetomidine-detecting strip exists yet, and to update your training materials to say plainly: prolonged sedation after full naloxone dosing is not a reason to give up — it can mean a second drug is in play, not treatment failure.

We’ve tracked this same drug-supply displacement pattern before in our crisis-data coverage and in our broader opioid reporting — each time, the lag between a new adulterant’s spread and frontline training catching up has cost real time. This is that lag, happening again, right now.